Clinical Trial Update: Immunogenicity & Safety Study of Adenovirus Type 5 (AD5) Based Oral Norovirus Vaccines [Phase 1, Phase 2]

View source ↗

Summary

Update on a Phase 1/2 study of an adenovirus type 5–based oral norovirus vaccine from Vaxart, reporting immunogenicity and safety results; trial completed with …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Norovirus Infection

Drugs mentioned

• AD5-based oral norovirus vaccine (Adenovirus type 5 vector-based oral norovirus vaccine)

Snippet

Sponsor: Vaxart | Conditions: Norovirus Infections | Phase 1, Phase 2 | Status: COMPLETED | Results posted: 2024-05-22